Global down-regulation of gene expression in the brain using RNA interference, with emphasis on monoamine transporters and GPCRs: Implications for target characterization in psychiatric and neurological disorders

Journal of Receptors and Signal Transduction

Volumn 26, Issue 5-6, 2006, Pages 527-547

  Hoyer, Daniel ^a,b   Thakker, Deepak R ^c   Natt, François ^a   Maier, Rainer ^a   Huesken, Dieter ^a   MÜller, Matthias ^a   Flor, Peter ^a   Van Der Putten, Herman ^a   Schmutz, Markus ^a   Bilbe, Graeme ^a   Cryan, John F ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MEDTRONIC INC   (United States)

^d UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Anxiety; Citalopram; Depression; Dopamine and serotonin transporters; Forced swim test; GBR12099; In vivo; Locomotor activity; RNA interference

Indexed keywords

CARRIER PROTEIN; CITALOPRAM; DOPAMINE TRANSPORTER; ENHANCED GREEN FLUORESCENT PROTEIN; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; MONOAMINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SMALL INTERFERING RNA; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN; BRAIN REGION; CONFERENCE PAPER; CONTROLLED STUDY; DOWN REGULATION; FORCED SWIMMING TEST; GENE EXPRESSION REGULATION; HYPERACTIVITY; IMMOBILIZATION; INVERTEBRATE; LOCOMOTION; MALE; MAMMAL; MENTAL DISEASE; MOUSE; NEUROLOGIC DISEASE; NEUROPSYCHIATRY; NONHUMAN; PLANT; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; BRAIN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOWN-REGULATION; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; LOCOMOTION; MENTAL DISORDERS; MICE; NERVOUS SYSTEM DISEASES; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; RNA, SMALL INTERFERING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

INVERTEBRATA; MAMMALIA;

EID: 33845205995     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.1080/10799890600929663     Document Type: Conference Paper

References (42)

1. Robinson ES, Nutt DJ, Jackson HC, Hudson AL. Antisense oligonucleotides in psychopharmacology and behaviour: Promises and pitfalls. J Psychopharmacol 1997, 11, 259-269.
2. Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL. Efficient and specific downregulation of prion protein expression by RNAi. Biochem Biophys Res Commun 2003, 305, 548-551.
3. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu, Zn superoxide dismutase. J Neurochem 2005, 92, 362-367.
4. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 2004, 10, 3667-3677.
5. Robinson R. RNAi therapeutics: How likely, how soon? PLoS Biol 2004, 2, e28.
6. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004, 351, 1772-1777.
7. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004, 101, 1892-1897.
8. Bitko V, Barik S. Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 2001, 1, 34-44.
9. Dillon CP, Sandy P, Nencioni A, Kissler S, Rubinson DA, Van Parijs L. RNAi as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol 2005, 67, 147-173.
10. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806-811.
11. Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA, Troy CM. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004, 24, 10040-10046.
12. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431, 343-349.
13. Thakker DR, Hoyer D, Cryan JF. Interfering with the brain: use of RNA interference (RNAi) for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol Ther 2006, 109, 413-438.
14. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P, Wishart W, Hall J. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004, 32, e49.
15. Davies W. Knockdown not knockout. Drug Discovery Today 2005, 10, 157-158.
16. Thakker DR, Natt F, Hüsken D, Maier R, Müller M, van der Putten H, Hoyer D, Cryan JF. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain using nonviral RNA interference. Proc Natl Acad Sci USA 2004, 101, 17270-17275.
17. Thakker DR, Natt F, van der Putten H, Maier R, Hoyer D, Cryan JF. siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain induces antidepressant-like effects. Mol Psychiatry 2005, 10, 782-789.
18. Hüsken D, Asselbergs F, Kinzel B, Natt F, Weiler J, Martin P, Haner R, Hall J. mRNA fusion constructs serve in a general cell-based assay to profile oligonucleotide activity. Nucleic Acids Res 2003, 31, e102.
19. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates, 2nd ed. London: Academic Press, 2001.
20. B receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004, 29, 1050-1062.
21. Cryan JF, Dalvi A, Jin SH, Hirsch BR, Lucki I, Thomas SA. Use of dopamine-β-hydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 2001, 298, 651-657.
22. Cryan JF, Mombereau C. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 2004, 9, 326-357.
23. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 2001, 155, 315-322.
24. Holmes A, Yang RJ, Murphy DL, Crawley JN. Evaluation of antidepressant-related behavioral responses in mice lacking the serotonin transporter. Neuropsychopharmacology 2002, 27, 914-923.
25. Bischoff S, Barhanin J, Bettler B, Mulle C, Heinemann S. Spatial distribution of kainate receptor subunit mRNA in the mouse basal ganglia and ventral mesencephalon. J Comp Neurol 1997, 379, 541-562.
26. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A. Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci 1999, 19, 10494-10501.
27. Hommel JD, Sears RM, Georgescu D, Simmons DL, DiLeone RJ. Local gene knockdown in the brain using viral-mediated RNA interference. Nat Med 2003, 9, 1539-1544.
28. Van den Haute C, Eggermont K, Nuttin B, Debyser Z, Baekelandt V. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum Gene Ther 2003, 14, 1799-1807.
29. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004, 10, 816-820.
30. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002, 20, 1006-1010.
31. Chao J, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med 2004, 55, 113-132.
32. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28, 325-334.
33. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003, 70, 83-244.
34. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S. Preclinical models: status of basic research in depression. Biol Psychiatry 2002, 52, 503-528.
35. Sisodia SS, St George-Hyslop PH. γ-Secretase, Notch, Aβ and Alzheimer's disease: Where do the presenilins fit in? Nat Rev Neurosci 2002, 3, 281-290.
36. Isacson R, Kull B, Salmi P, Wahlestedt C. Lack of efficacy of 'naked' small interfering RNA applied directly to rat brain. Acta Physiol Scand 2003, 179, 173-177.
37. 2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood. Neuroscience 2004, 129, 521-528.
38. Makimura H, Mizuno TM, Mastaitis JW, Agami R, Mobbs CV. Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci 2002, 3, 18.
39. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379, 606-612.
40. Thakker DR, Schmutz M, Maier R, Natt R, Hüsken D, van der Putten H, Flor PJ, Hoyer D, Cryan JF. siRNA-induced knockdown of the group III metabotropic glutamate receptor mGluR7 in the adult mouse brain induces an anxiolytic-like response. Soc Neuroscience Abstr 2005, 678.10.
41. Thakker DR, Hoyer D, Schmutz M, Maier R, Natt F, Hüsken D, Sansig G, van der Putten H, Flor PJ, Cryan JF. mGlur7 plays a key role in the modulation of anxiety behavior: Evidence from mGlur7-knockout mice and siRNA-induced knockdown in the adult mouse brain. Neuropharmacology 2005, 49 (Suppl 1), 275.
42. Cryan JF, Mitsukawa K, Thakker DR, Mombereau C, Lötscher E, Uzunov DP, Natt F, Huesken D, Maier R, McAllister K, Hoyer D, van der Putten H, Flor PJ. mGluR7: A novel therapeutic target for stress-related disorders. Neuropsychopharmacology 2005, 30 (Suppl), S31.